Performance of vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of β-lactam resistance

Journal of Clinical Microbiology

Volumn 46, Issue 6, 2008, Pages 2095-2098

  Mazzariol, Annarita ^a   Aldegheri, Marco ^a   Ligozzi, Marco ^a   Cascio, Giuliana Lo ^b   Koncan, Raffaella ^a   Fontana, Roberta ^a,c  

^a UNIVERSITY OF VERONA   (Italy)

^b Azienda Ospedaliera   (Italy)

^c Clinical Microbiology Laboratory   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACCURACY; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; INTERMETHOD COMPARISON; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CEFTAZIDIME; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS;

PSEUDOMONAS AERUGINOSA;

EID: 45149120548     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02216-07     Document Type: Article

References (18)

1. Burns, J. L., L. Saiman, S. Whittier, J. Krzewinski, Z. Liu, D. Larone, S. A. Marshall, and R. N. Jones. 2001. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 39:257-260.
2. Burns, J. L., L. Saiman, S. Whittier, D. Larone, J. Krzewinski, Z. Liu, S. A Marshall, and R.N. Jones. 2000. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J. Clin. Microbiol. 38:1818-1822.
3. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing. 17th informational supplement M100-S17. CLSI, Wayne, PA.
4. Cornaglia, G., L. Guan, R. Fontana, and G. Satta. 1992. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities. Antimicrob. Agents Chemother. 36:1902-1908.
5. Cornaglia, G., M. Akova, G. Amicosante, R. Cantón, R. Cauda, J.-D. Docquier, M. Edelstein, J.-M. Frère, M. Fuzi, M. Galleni, H. Giamarellou, M. Gniadkowski, R. Koncan, B. Libisch, F. Luzzaro, V. Miriagou, F. Navarro, P. Nordmann, L. Pagani, L. Peixe, L. Poirel, M. Souli, E. Tacconelli, A. Vato poulos, and G. M. Rossolini. 2007. Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int. J. Antimicrob. Agents 29:380-388.
6. Donay, J.-L., D. Mathieu, P. Fernandes, C. Prégermain, P. Bruel, A. Wargnier, I. Casin, F. X. Weill, P. H. Lagrange, and J. L. Herrmann. 2004. Evaluation of the automated Phoenix system for potential routine use in the clinical microbiology laboratory. J. Clin. Microbiol. 42:1542-1546.
7. Jones, R. N., D. J. Biedenbach, S. A. Marshall, M. A. Pfaller, and G. V. Doern. 1998. Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. Diagn. Microbiol. Infect. Dis. 32:107-110.
8. Jorgensen, J. H. 1993. Selection criteria for an antimicrobial susceptibility testing system. J. Clin. Microbiol. 31:2841-2844.
9. Joyanes, P., M. D. C. Conejo, L. Martìnez-Martìnez, and E. J. Perea. 2001. Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples. J. Clin. Microbiol. 39:3247-3253.
10. Juretschko, S., V. J. LaBombardi, S. A. Lerner, P. C. Schreckenberger, and the Pseudomonas AST Study Group. 2007. Accuracy of β-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2). J. Clin. Microbiol. 45:1339-1342.
11. Karlowsky, J. A., M. K. Weaver, C. Thornsberry, M. J. Dowzicky, M. E. Jones, and D. F. Sahm. 2003. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J. Clin. Microbiol. 41:3339-3343.
12. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43:1584-1590.
13. Poole, K. 2007. Efflux pumps as antimicrohial resistance mechanisms. Ann. Med. 39:162-176.
14. Sader, H. S., T. R. Fritsche, and R. N. Jones. 2006. Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J. Clin. Microbiol. 44:1101-1104.
15. Saegeman, V., P. Huynen, J. Colaert, P. Melin, and J. Verhaegen. 2005. Susceptibility testing of Pseudomonas aeruginosa by the Vitek 2 system: a comparison with E-test results. Acta Clin. Belg. b:3-9.
16. Sanders, C. C., M. Peyret, E. Smith Moland, C. Shubert, K. S. Thomson, J.-M. Boeufgras, and W. E. Sanders, Jr. 2000. Ability of the VITEK 2 Advanced Expert System to identify β-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J. Clin. Microbiol. 38: 570-574.
17. Toleman, M. A., D. Biedenbach, D. M. Bennett, R. N. Jones, and T. R. Walsh. 2005. Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Program. J. Antimicrob. Chemother. 55:61-70.
18. Trias, J., and H. Nikaido. 1990. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:52-57.